UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER...

1

American Association for Cancer Research Annual Meeting

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

April 1 – 5, 2017Washington, DCUCSF Presentation Brochure

As president of the UCSF Helen Diller Family Comprehensive Cancer

Center, one of my key priorities is to initiate and advance programs

that are developing new anticancer drugs making significant impact

on helping cancer patients live longer and better lives. I recognize this

goal is best accomplished by working in partnership with the broader

life science industry. This searchable abstract book of UCSF research

presented at AACR is a resource for potential partners interested in

identifying world-class faculty engaged in basic science and clinical

oncology research.

As an NCI-designated comprehensive cancer center, UCSF is

recognized for our outstanding science, extensive resources, depth

and breadth of our research in basic, clinical, and population sciences,

as well as cutting edge research that bridges these scientific areas.

Practically, this means that our clinicians and basic scientists work

closely together to (1) identify, develop, and optimize novel therapeutics

for biological efficacy and clinical utility, (2) assess tumor status and

responsiveness to current therapies, (3) develop biomarkers for patient

stratification and therapeutic response, and (4) advance supportive

care options to mitigate the toxicities associated with chemotherapy.

UCSF is home to many of world’s finest oncology clinicians and

scientists. I invite you learn more about our work and expertise

by reaching out to our faculty during this meeting. If you have any

additional questions or need any assistance with your outreach,

please contact the Director of Strategic Alliances for the Cancer

Center: Cammie Edwards ([email protected]).

Wishing you a very productive meeting and we look forward to

future discussions and collaborations.

Alan Ashworth, PhD, FRS President, UCSF Helen Diller Family Comprehensive Cancer Center

Committed to Advancing Development of Improved Cancer Therapies, Imaging Modalities, and Biomarkers

Alan Ashworth, PhD, FRSPresident, UCSF Helen Diller Family Comprehensive Cancer Center

Senior Vice President for Cancer Services, UCSF Health

Professor of Medicine, Division of Hematology/Oncology, Department of Medicine

2

The “comprehensive” designation—NCI’s highest ranking, awarded only after a rigorous evaluation process—recognizes UCSF’s excellence in basic research, clinical research, population based research, outreach and education, and our ability to integrate these diverse research approaches to cancer and turn them into clinical practice.

A Designated NCI Comprehensive Cancer Center Since 1999

HDFCCC Overview

Our Success is Driven by Our FacultyHDFCCC Membership: 415 Members & Affiliate Members2 Nobel Laureates

3 Albert Lasker Award winners

8 Howard Hughes Medical Investigators

14 Members of the National Academy of Sciences

20 Members of the Institute of Medicine

22 Fellows of the American Academy of Arts and Sciences

6 Fellows of the Royal Society

3

Working Together Advancing the Understanding and Treatment of Cancer

Multi-Disciplinary Research Programs• Breast Oncology

• Cancer Control

• Cancer Genetics

• Cancer, Immunity, and Microenvironment

• Developmental Therapeutics

• Hematopoietic Malignancies

• Neurologic Oncology

• Pediatric Malignancies

• Prostate Cancer

• Tobacco Control

Key Initiatives• Precision Imaging of Cancer and Therapy

• Cancer Immunotherapeutics

• Global Oncology

• Center for BRCA Research

• UCSF 500

• Cell Engineering

• Target Validation Initiative

• The San Francisco Cancer Initiative (SF CAN)

Multi-Disciplinary Clinical Programs • GU Oncology (non Prostate)

• GI (includes Pancreas Cancer)

• Thoracic Oncology

• Cutaneous Oncology

• Head and Neck Cancer

• Sarcoma

• Endocrine

• Gynecologic Oncology

• Breast Oncology

• Prostate Cancer

Translating Laboratory Discoveries into Improved Patient CareWhether it is advancing a new vaccine based immunotherapy, developing a new diagnostictest to distinguish benign moles from malignant melanoma or pioneering new adaptive clinicaltrial designs, UCSF success in translating laboratory discoveries into improved patient carecomes from its faculty and culture of exploration and collaboration. With over 400 facultyrelentlessly pursuing oncology research and clinical practice, we continue to make significantstrides in understanding the biology of disease and improving patient outcomes withadvanced clinical care.

HDFCCC Overview

4

• Biostatistics

• Clinical Research Support

• Genome Analysis

• Laboratory for Cell Analysis

• Immunohistochemistry & Molecular Pathology

• Mouse Pathology

• Preclinical Therapeutic Testing

• Bio-specimen Banking

• Tobacco Biomarkers

• Bioinformatics

• Computational Biology

UCSF consistently ranks among

the top U.S. biomedical research

organizations in cancer-specific

federal funding. In 2016, UCSF

received more than $92M from the

National Cancer Institute.

HDFCCC Overview

Core Capabilities Supporting Our Programs

Approximately one-quarter of the

University’s ~2,200 full-time faculty

members work in cancer research or

cancer care.

5

UCSF faculty have a long history of working with industry partners translating discoveries into products that ultimately improve patient care. We are experienced in establishing and executing on a wide range of successful partnerships. If you are interested in learning more about working with the HDFCCC and its faculty, please contact:

Cammie Edwards, PhDDirector of Strategic Alliances, HDFCCC

• On average, UCSF has 200-300 new invention disclosures per year

• An estimated 90 life science start-up companies have been spawnedfrom the University’s labs, including Genentech, Chiron, and Intellikine

• Included among UCSF patents are top revenue producers, such as

UCSF IN THE NEWS (Click on link to read story)

UCSF, Pfizer Renew Research Collaboration, Citing Progress in Drug Discovery Researchhttp://cancer.ucsf.edu/news/2017/01/09/ucsf-pfizer-renew-research-collaboration-citing-progress-in-drug-discovery-research.8092

Search Engine: How Artificial Intelligence Techniques Are Aiding the Hunt for New Drugshttp://cancer.ucsf.edu/news/2017/01/04/search-engine-how-artificial-intelligence-techniques-are-aiding-the-hunt-for-new-drugs.8079

New Targeted Chemotherapy Technology Proves Effective in Micehttp://cancer.ucsf.edu/news/2016/12/12/new-targeted-chemotherapy-technology-proves-effective-in-mice.8063

Mutant Protein Linked to Spread of Lung Cancer within the Bodyhttp://cancer.ucsf.edu/news/2016/11/21/mutant-protein-linked-to-spread-of-lung-cancer-within-the-body.7986

‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumorshttp://cancer.ucsf.edu/news/2016/09/29/cellbots-chase-down-cancer-deliver-drugs-directly-to-tumors.7921

Dr. Amit Sabnis Awarded the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research. The award will be used to further his research in identifying the molecular mechanism behind an oncogene-directed therapy in rhabdomyosarcoma and defining the PAX3-FOXO1 translatome.

- Hepatitis B vaccine

- Bovine growth hormone

- Barrier repair lipids

- Yeast expression vector

- Magnetic resonance imaging

Partnering with UCSF HDFCCC

http://cancer.ucsf.edu/news/2017/01/09/ucsf-pfizer-renew-research-collaboration-citing-progress-in-drug-discovery-research.8092

http://cancer.ucsf.edu/news/2017/01/04/search-engine-how-artificial-intelligence-techniques-are-aiding-the-hunt-for-new-drugs.8079

http://cancer.ucsf.edu/news/2016/12/12/new-targeted-chemotherapy-technology-proves-effective-in-mice.8063

http://cancer.ucsf.edu/news/2016/11/21/mutant-protein-linked-to-spread-of-lung-cancer-within-the-body.7986

http://cancer.ucsf.edu/news/2016/09/29/cellbots-chase-down-cancer-deliver-drugs-directly-to-tumors.7921

Presentations

6 *UCSF authors in bold

Retooling CRISPR to turn genes on and off

Authors*: Luke A. Gilbert

Presentation #: Presentation Date/Time: April 1, 2017, 8:30 - 8:55AM Location: Room 207, Level 2, Washington Convention Center Presentation: Educational Session

Weissman Research Interests: Our laboratory is looking at how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology. We are developing experimental and analytical approaches for exploring the organizational principles of biological systems and globally monitoring protein translation through ribosome profiling. Additionally, our research focuses on identifying and understanding the machinery necessary for efficient folding, as well as studying the mechanism and consequences of protein misfolding. We are also developing experimental and analytical approaches for exploring the organizational principles of complex biological systems and for monitoring protein translation in vivo with unprecedented precision and depth.

http://weissmanlab.ucsf.edu/research/research.html

__________________________________________________________________________

Brain cancer immunotherapy

Authors*: Hideho Okada

Presentation #: Presentation Date/Time: April 1, 2017, 10:15 - 12:15 PM Location: Independence Ballroom E-H, Meeting Level 4, Marriott Marquis DC Presentation: Educational Session

Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.

http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html

PresentationsView full abstracts on line at: http://www.abstractsonline.com/pp8/#!/4292*UCSF authors in bold

Saturday, April 1, 2017

Presentations


Tissue Tension: The extracellular martrix and PDAC phenotype

Authors*: Valerie M. Weaver Presentation #:Presentation Date/Time: April 1, 2017, 11:15 - 11:40 AM Location: Room 151, Level 1, Washington Convention Center Presentation: Educational Session

Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.

http://weaverlab.ucsf.edu

__________________________________________________________________________

Transforming breast cancer treatment with CDK4/6 inhibitors

Authors*: Hope S. Rugo

Presentation #: Presentation Date/Time: April 1, 2017, 1:30 - 1:55 AM Location: Room 145, level 1, Washinton Convention Center Presentation: Educational Session

Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the safety committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.

http://cancer.ucsf.edu/people/profiles/rugo_hope.3648

Presentations


Translating the cancer genome one codon at a time and its therapeutic implications

Authors*: Davide Ruggero

Presentation #: Presentation Date/Time: April 1, 2017, 1:00 - 1:25 PM Location: Room 206, Level 2, Washington Convention Center Presentation: Educational Session

__________________________________________________________________________

Response to checkpoint therapy and exhausted CTL in the tumor microenvironment

Authors*: Adil I. Daud

Presentation #: Presentation Date/Time: April 1, 2017, 1:00 - 1:20 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Methods Workshop

Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL- 12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and potentially other cancers).

http://cancer.ucsf.edu/people/profiles/daud_adil.3622

Presentations


A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma

Authors*: Margaret A. Tempero

Presentation #: Presentation Date/Time: April 1, 2017, 5:30 - 5:55 PM Location: Room 202, Level 2, Washington Convention Center Presentation: Special Session

Tempero Research Interests: Director of the UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, Dr. Tempero oversees research projects from risk assessment to early detection, biology, and therapeutics in PNET and PDAC. Her personal research career has focused on the area of investigational therapeutics in PDAC. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Dr. Tempero’s group developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival, and is currently assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. She is a DreamTeam P.I. on a SU2C grant evaluating innovative immunotherapy approaches, and is co-PI on a U01 award to establish high risk cohorts for testing early diagnosis biomarkers. She has served as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000, and on several SABs including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.

http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701

Presentations


Targeting BRD4 overcomes cetuximab resistance in HNSCC

Authors*: Toni Brand, Yan Zeng, Brandon Leonard, Rachel O’ Keefe, Hua Li, Daniel Johnson, Jennifer Grandis, Neil E. Bhola

Presentation #: 95 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 4 Presentation: Poster Session/ Board #16

Head and Neck Cancer Lab: is dedicated to increasing our understanding of head and neck squamous cell carcinoma (HNSCC) to develop new treatment and prevention approaches. One overarching theme is to identify predictive biomarkers that will identify which treatment(s) are most effective for individual patients, thus allowing for personalized medicine. Translational resources we have developed to support our projects include a large collection of patient-derived xenografts (PDXs) and tissue microarrays containing over 500 human HNSCC research samples linked to a professionally curated clinical and pathologic database that includes information on treatment and survival. In addition to basic and translational research, we also have experience conducting investigator-initiated clinical trials of novel therapeutics, including an antisense EGFR (epidermal growth factor receptor) gene therapy and a novel decoy oligonucleotide targeting STAT3 (signal transducer and activator of transcription).

https://ohns.ucsf.edu/signaling-lab

__________________________________________________________________________

Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways

Authors*: Mitsuho Imai-Sumida, Takeshi Chiyomaru, Shahana Majid, Priyanka Kulkarni, Pritha Dasgupta, Sharanjot Saini, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Hannah Nip, Rajvir Dahiya, Yuichiro Tanaka, Soichiro Yamamura


Sunday, April 2, 2017

Presentations


Site specific risk factors for colorectal cancer

Authors*: Samir Gupta, Ranier Bustamante, Ashley Earles, Maria E. Martinez, Karen Messer, Christina D. Williams, Andrew J. Gawron, Tonya Kaltenbach, Lin Liu


Kaltenbach Research Interests: Dr. Kaltenbach is an active researcher and educator in the field of advanced endoscopic imaging and therapy. She has numerous publications on non-polypoid neoplasia, image enhanced endoscopy and endoscopic mucosal resection. She is currently leading a national intiative to measure and report colonoscopy quality across the VAs, and moreover, aims to improve colonoscopy quality through provider feedback and teaching. She played a major role in the recent efforts to enhance the quality of colonoscopy for the surveillance and management of dysplasia in inflammatory bowel disease throughout the world. These efforts have brought forward a practice paradigm that is built on evidence based medicine, and have included a new consensus guideline, atlas, teaching video and practice and implementation algorithm.

http://profiles.ucsf.edu/tonya.kaltenbach

__________________________________________________________________________

Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells

Authors*: Sung Eun Kim, Man-Tzu Wang, Frank McCormick

Presentation #:435 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 18 Presentation: Poster Session/ Board #16

Presentations


The role of miR-24 as a race-related genetic factor in prostate cancer

Authors*: Yutaka Hashimoto, Marisa Shiina, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Yozo Mitsui, Mitsuho Sumida, Guoren Deng, Laura Tabatabai, Deepak Kumar, Rajvir Dahiya


Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/UCSF under the leadership of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney tumor progression and metastasis.

https://urology.ucsf.edu/people/rajvir-dahiya

__________________________________________________________________________

Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African Americans and Caucasians

Authors*: Marisa Shiina, Yutaka Hashimoto, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Shahryari Varahram, Priyanka Kulkarni, Prita Dasgupta, Mitsuho Sumida, Guoren Deng, Rajvir Dahiya


Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/UCSF under the leadership of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney tumor progression and metastasis.

https://urology.ucsf.edu/people/rajvir-dahiya

Presentations


Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients

Authors*: Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong


Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.

http://hemonc.ucsf.edu/fonglab/

__________________________________________________________________________

Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response

Authors*: James C. Lee, Adil Daud, Jeff Bluestone

Presentation #: 683A Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 28 Presentation: Poster Session/ Board #30

Bluestone Research Interests: Our lab is broadly focused on understanding mechanisms regulating T cell activation. We have developed soluble receptor antagonists; mAbs & animals deficient in individual members of TCR & co-stimulatory pathways to define their individual roles in transplant rejection & autoimmunity including a special emphasis on regulatory T cells (Treg). We have also adapted animal studies to use biologics & cell-based therapies to develop therapeutics that can be used in humans with autoimmunity & under conditions of allotransplant rejection. A strong role for antigen-specific Tregs has been found in these model systems. Thus, the major goal of our work is to identify the antigen-specificity of thymic- & peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, our lab is determining mechanisms that control Treg stability with the goal of developing approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity & cancer.

http://bluestone.ucsf.edu

Presentations


TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM

Authors*: Qi Liu, Haydeliz Martinez-Ruiz, John Murnane, Simon N. Powell, Mary Helen Barcellos-Hoff

Presentation #: 831 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 39Presentation: Poster Session/ Board #9

Barcellos-Hoff Research Interests: The Barcellos-Hoff lab has actively pursued the translational potential of TGFβ inhibition in the context of radiotherapy in human cancer based on preclinical studies in mouse brain, breast, and lung tumor models. TGFβ inhibitors increase radiation sensitivity (i.e., 10-70% less dose is needed to reduce survival by 90%), inhibit molecular recognition of DNA damage, compromise DNA repair, and increases tumor control by radiation. Although most cancers are resistant to TGFβ growth control, most cancer cells appear to require TGFβ to effectively execute the genotoxic stress program, which provides a novel avenue to improve therapeutic response.

http://cancer.ucsf.edu/people/profiles/barcellos-hoff_mary.6915

__________________________________________________________________________

Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin

Authors*: Mathieu Daynac, Claudia K. Petritsch


Petritsch Research Interests: The Petritsch Lab uses pharmacological, molecular, and in vivo and ex vivo techniques, to uncover the mechanism for cell fate decisions in oligodendrocyte precursor cells, in the healthy and diseased brain. Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs) and accomplish myelination in the central nervous system to regulate axonal function. Although OPCs are the most abundant proliferative population in the adult and ageing brain, little is known about the underlying molecular regulation of OPC functions. In our lab, we are examining whether OPCs in the adult central nervous system decide about their fate by undergoing asymmetric divisions, whether the underlying mechanism of asymmetric cell divisions in mammalian cells diverge from the process found in Drosophila neuroblasts, whether this divergence involves epigenetic regulators and is there a cell intrinsic or extrinsic mechanism that determines whether OPC divisions are symmetrical or asymmetrical.

http://petritschlab.ucsf.edu

Presentations


Oncology model fidelity scores

Authors*: Debajyoti Datta, Theodore Goldstein, Zhiping Gu, Atul Butte

Presentation #: LB-006 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 34 Presentation: Poster Session/ Board #5

Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to truly novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab uses the bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic, phenotypic, and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed tools for indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to explore human physiology using electronic health record data and in the medical risk estimation from whole genomes.

http://buttelab.ucsf.edu

__________________________________________________________________________

The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich ecosystem for collaborative discovery in the cloud

Authors*: Adam C. Resnick, Phillip B. Storm, Angela J. Waanders, Jena V. Lilly, Rishi R. Lulla, Sabine Mueller, Michael Prados, Leonard S. Sender, Allison Heath, Alex S. Felmeister, Anthony Cros, Yuankun Zhu, Pichai Raman


Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

http://cancer.ucsf.edu/people/profiles/prados_michael.3603

Presentations


The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research

Authors*: Frank McCormick, Frederick Streitz, Andrew Stephen, Frantz L. Jean-Francois, Thomas J. Turbyville -Invited Speakers Presentation #: Presentation Date/Time: April 2, 2017, 2:45 - 4:15 PM Location: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Section

__________________________________________________________________________

Meet the Research Icon: Bruce M. Alberts, PhD, Organized by the Associate Member Council (AMC)

Authors*: Bruce M. Alberts

Presentation #: Presentation Date/Time: April 2, 2017, 3:00 - 3:30 PM Location: AACR central Amphitheater (Booth 1125), Lower Level, Washington Convention Center Presentation: Meet the Research Icon

Presentations


Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Authors*: Matthew J. Hangauer, Vasanthi S. Viswanathan, Matthew J. Ryan, Dhruv Bole, Jake Eaton, Stuart L. Schreiber, Frank McCormick, Michael T. McManus

Presentation #: 1006 Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm Location: Room 152, Level 1, Washington Convention CenterPresentation: Minisymposium

McManus Research Interests: The McManus lab studies fundamental processes relating to the regulation of gene expression. We take high-throughput approaches, analyzing hundreds of thousands to millions of experiments at once, using unique and complex libraries coupled to deep sequencing. Our systems span from cell culture to in vivo models, focusing on a broad array of disease relevant tissues. From cancer to diabetes, we develop novel technologies to help us better understand how genes are regulated and how they function in cells. We aim to uncover the dark matter of the genome, to help unravel the beautiful genomic complexity of pathways and how genes interact in development and disease.

http://mcmanuslab.ucsf.edu

__________________________________________________________________________

Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity

Authors*: David Q. Wang, Jason R. Quiros, Chien-Chun S. Pai, Lawrence H. Fong, Jeffrey A. Bluestone, Michel J. DuPage

Presentation #: 1014 Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm Location: Room 146, Level 1, Washington Convention CenterPresentation: Minisymposium DuPage Research Interests: The DuPage lab is focused on examining the interface of the immune system and cancer. We aim to establish a new paradigm for augmenting immune responses against cancer by uncovering and subsequently targeting mechanisms that control T regulatory cell programming within the tumor microenvironment. We have identified key intracellular pathways, both signaling cascades and epigenetic enzymes, that when targeted, selectively reprogram intratumoral T regulatory cell function to enhance anti-cancer immunity. Our approach utilizes sophisticated genetic tools to modify T cells and tumor cells in a dynamic fashion during tumor progression and in the context of the most advanced pre-clinical cancer models of the human disease.

http://profiles.ucsf.edu/michel.dupage

Presentations


Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer

Authors*: Michael A. Moses, Yeong Sang Kim, Genesis Rivera-Marquez, Matthew J. Watson, Sunmin Lee, Andrea Kravats, Sue Wickner, Jason Gestwicki, Jane Trepel, Len Neckers

Presentation #: 1180 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 5 Presentation: Poster Session/ Board #25

Gestwicki Research Interests: We are interested in how molecular chaperones, such as Hsp70 and Hsp90, work together to maintain protein homostasis, which is the balance of protein folding, trafficking and turnover. Understanding this delicate balance is important because protein homeostasis is dramatically disrupted in many diseases, especially neurodegeneration and cancer. Our approach is to create small molecules that disrupt (or promote) interactions between chaperones. Using these chemical probes, we perturb protein-protein interactions and learn how this chaperone network is “wired”. These studies have taken us into many exciting areas of biotechnology and chemical biology.

http://gestwickilab.ucsf.edu

__________________________________________________________________________

FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination

Authors*: Victoria E. Wang, Jeffrey Settleman, Frank McCormick


Monday, April 3, 2017

Presentations


Pathway analysis of insulin-like growth factor candidate genes and risk of pediatric rhabdomyosarcoma

Authors*: Libby Morimoto, XIaorong Shao, Anand Chokkalingam, Joseph Wiemels, Xiaomei Ma, Catherine Metayer


Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.

http://profiles.ucsf.edu/joe.wiemels

__________________________________________________________________________

Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening

Authors*: Rebecca E. Graff, Thomas J. Hoffmann, Michael N. Passarelli, Nima C. Emami, Lori C. Sakoda, Eric Jorgenson, Laurel A. Habel3, Jun Shan, Dilrini K. Ranatunga, Charles P. Quesenberry, Jr., Chun R. Chao4, Nirupa R. Ghai, David Aaronson, Joseph Presti, Tobias Nordström, Zhaoming Wang, Sonja I. Berndt, Stephen J. Chanock, Jonathan D. Mosley, Robert J. Klein, Mridu Middha, Hans Lilja, Olle Melander, Mark N. Kvale, Pui-Yan Kwok, Catherine Schaefer, Neil Risch, Stephen K. Van Den Eeden, John S. Witte


Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.

http://wittelab.ucsf.edu/pages/research

Presentations


Identification of pleiotropic cancer susceptibility variants from genome-wide association studies reveals functional characteristics

Authors*: Yi-Hsuan Wu, Rebecca E. Graff, Michael N. Passarelli, Thomas J. Hoffmann, Elad Ziv, John S. Witte

Presentation #:1310 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 12 Presentation: Poster Session/ Board #11



__________________________________________________________________________

Germline genetic signals across multiple aggressive prostate cancer phenotypes

Authors*: Caroline G. Tai, Nima C. Emami, Thomas J. Hoffmann, Lori C. Sakoda, Eric Jorgenson, Laurel A. Habel, Jun Shan, Dilrini K. Ranatunga, Chun R. Chao, Nirupa R. Ghai, David Aaronson, Joseph Presti, Catherine Schaefer, Neil Risch, Stephen K. Van Den Eeden, John S. Witte

Presentation #:1316 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 12 Presentation: Poster Session/ Board #17



Presentations


Non-additive and interaction effects of HLA class 2 polymorphism contributing to risk of glioma

Authors*: Chenan Zhang, Kyle Walsh


Walsh Research Interests: Dr. Walsh’s research program is divided into two components: genetic epidemiology and functional genomics. The epidemiology component focuses on the use of genomic data from large population-based cohorts to identify the causes of cancer. This computational work stresses statistical methodologies for “gene hunting”, including GWAS, fine-mapping, admixture mapping, and whole-genome sequencing. This ongoing work has identified novel risk factors for glioma and childhood leukemia. The functional genomics component investigates the biological impact of genetic variants linked to cancer risk. Dr. Walsh’s laboratory utilizes numerous techniques, including: digital droplet PCR, ChIP, FISH, and luciferase reporter assays. Special focus is given to the interface of the inherited genome and the tumor genome. Deregulation of tumor suppression mechanisms, such as telomere-induced cell senescence, is of particular interest. http://neurosurgery.ucsf.edu/index.php/about_us_faculty_walsh

__________________________________________________________________________

Variable drug responses characterize the functional heterogeneity of Nf1 null tumors

Authors*: Daniela Pucciarelli, Ganesh Krishnamurthi, Steve Braunstein, Jean L. Nakamura


Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using this information to develop better therapies. A second area of research is trying to understand why second cancers develop in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we expect to understand the biological processes leading to second cancers, and one day prevent these complications.

https://radonc.ucsf.edu/jean-nakamura

Presentations


Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS

Authors*: Timothy Tran, Sathiya Dharmaiah, Oleg Chertov, Timothy Waybright, William Gillette, Dominic Esposito, Dwight Nissley, Frank McCormick, Andrew Stephen, Dhirendra Simanshu

Presentation #: 1366 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 14 Presentation: Poster Session/ Board #17

__________________________________________________________________________

EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling

Authors*: Evan Markegard, Ellen L. Mercado, Jillian M. Silva, Jacqueline Galeas, Marena I. Trinidad, Anatoly Urisman, Frank McCormick


Presentations


Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients

Authors*: David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong




__________________________________________________________________________

Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma

Authors*: Matthew Louis Hedberg, Noah Peyser, William Gooding, Hua Li, Toni Brand, Victor Olivas, Trever Bivona, Simion Choisea, Lin Wang, Jonas Johnson, Uma Duvvuri, Robert Ferris, Daniel Johnson, Patrick Ha, Julie Bauman, Jennifer Grandis


Grandis Research Interests: The Grandis lab has played a major role in determining the mutational landscape of head and neck squamous cell carcinoma (HNSCC) and is focused on determining the role of frequently mutated genes in this malignancy. PIK3CA is the most commonly altered is the most commonly altered oncogene in HNSCC. Prior work in colon cancer has suggested an association between regular aspirin use and extended survival in patients with PIK3CA mutations. Using a large cohort of patients with HNSCC, the Grandis lab has determined that chronic NSAID use is associated with dramatically improved survival in patients with altered PIK3CA. They have characterized the mechanism of action of PIK3CA mutations and the impact of NSAIDs on these mechanistic pathways. Further, they plan a large prospective clinical trial that will directly assess the therapeutic benefit of NSAIDs in HNSCC patients with specific mutational profiles.

http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048

Presentations


Tumor-specific copy number alterations uncover therapeutic opportunities in osteosarcoma

Authors*: Leanne C. Sayles, Marcus Breese, Amanda L. Koehne, Stanley Leung, Aviv Spillinger, Alex Lee, Avanthi Shah, Krystal Straessler, Sheri Spunt, Neyssa Marina, Damon Jacobson, Raffi S. Avedian, David G. Mohler, Steven DuBois, Douglas S. Hawkins, E. Alejandro Sweet-Cordero


Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work, we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.

https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106

__________________________________________________________________________

STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions

Authors*: Ami V. Desai, Garrett M. Brodeur, Jennifer Foster, Suzanne Shusterman, Amit J. Sabnis, Magaret Macy, Cynthia Wetmore, Ellen Basu, Zachary Hornby, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox

Presentation #: CT030 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 33 Presentation: Poster Session/ Board #6

Sabnis Research Interests: Dr. Sabnis’s research uses patient-derived models to identify and pre-clinically validate new therapies for high-risk pediatric sarcomas. In work with his mentor, Dr. Trever Bivona, and other collaborators at UCSF, he has developed a nascent program focusing on targets within protein homeostasis networks. In addition, he sees patients within the Early Phase Clinical Trials group of the UCSF Benioff Children’s Hospital Division of Pediatric Hematology-Oncology.

http://cancer.ucsf.edu/people/profiles/sabnis_amit.7897

Presentations


A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Authors*: Lawrence Fong, Michael Morris, Andrew Armstrong, Daniel Petrylak, Ulka Vaishampayan, Ajjai Alva, Jean Hoffman-Censits, Indrani Sarkar, Susheela Carroll, Christina Schiff, Oliver Sartor

Presentation #: CT031 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 33 Presentation: Poster Session/ Board #7



__________________________________________________________________________

Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial

Authors*: George Seed, Wei Yuan, Joaquin Mateo, Suzanne Carreira, Maryou Lambros, Gunther Boysen, Roberta Ferraldeschi, Susana Miranda, Ines Figueiredo, Ruth Riisnaes, Mateus Crespo, Daniel Nava Rodrigues, Eric Talevich, Dan Robinson, Priya Kunju, Yi-mi Wu, Robert Lonigro, Shahneen Sandhu, Arul Chinnayan, Johann De Bono

Presentation #: LB-044 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 34 Presentation: Poster Session/ Board #6

Talevich Research Interests: Dr. Talevich is a bioinformatician in the Clinical Cancer Genomics Laboratory (CCGL) at the UCSF Medical center, supporting clinical care and translational research efforts in precision medicine, including the UCSF 500 cancer gene panel service. His area of focus is the design and construction of genomic analysis pipelines to support short-read (Illumina) DNA and RNA sequencing of cancer samples for patient care, and the development of software and databases for sample tracking, quality control, genome characterization and mutation calling, and functional annotation to facilitate clinical review.

http://profiles.ucsf.edu/eric.talevich

Presentations


PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity

Authors*: Matthew J. Schiewer, Amy C. Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Shuang Zhao, Joseph Evans, Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Tapio Visakorpi, Ganesh Raj, Mark Rubin, Johann de Bono, Costas Lallas, Edouard Trabulsi, Leonard G. Gomella, Adam P. Dicker, Kevin Kelly, Beatrice Knudsen, Felix Feng, Karen E. Knudsen

Presentation #: LB-086 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 36 Presentation: Poster Session/ Board #11

Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers. https://radonc.ucsf.edu/felix-feng

__________________________________________________________________________

Forcing tumor progression and aggression

Authors*: Valerie M Weaver

Presentation #: Presentation Date/Time: April 3, 2017, 11:20 - 11:40 AM Location: Room 202, Level 2, Washington Convention CenterPresentation: Major Symposium



Presentations


Landscape analysis of the initial data release from AACR Project GENIE

Authors*: Ethan Cerami, Alexander S. Baras, Justin Guinney, Eva Lepisto, Trevor J. Pugh, Nikolaus Schultz, Thomas Stricker, Shawn M. Sweeney, Laura J. van’t Veer, Gerrit A. Meijer, Fabrice Andre, Victor E. Velculescu, Kenna R. Shaw, Mia A. Levy, Philippe L. Bedard, Barrett J. Rollins, Charles L. Sawyers

Presentation #: LB-102 Presentation Date/Time: April 3, 2017, 11:55 - 12:05 PM Location: Ballroom A-B, Level 3, Washington Convention Center Presentation: Major Symposium

van’t Veer Research Interests: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. Her laboratory investigates human kinases & how kinase inhibitors elicit response & resistance, which is also utilized to understand agent efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health Network, a 150,000 women cohort study evaluating new paradigms to enhance breast health. She leads the targeted genome testing of 100,000 women for 9 breast cancer susceptibility genes and a selection of ~100 known susceptibility SNPs. She is one of the PIs for the NIH Big Data to Knowledge Center Translational Genomics, facilitating worldwide standardization of sharing annotated genomics data.

http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358

__________________________________________________________________________

MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease

Authors*: Hope S. Rugo, Sara M. Tolaney, Javier Cortés, Véronique Diéras, Debra A. Patt, Hans Wildiers, Shivani Nanda, Andrew G. Koustenis, Maura N. Dickler, José Baselga

Presentation #: CT044 Presentation Date/Time: April 3, 2017, 10:35 - 10:55 AM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Clinical Trials Plenary Session

Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the safety committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.

http://cancer.ucsf.edu/people/profiles/rugo_hope.3648

Presentations


Mechanisms of residual disease during targeted therapy

Authors*: Trever G. Bivona

Presentation #: Presentation Date/Time: April 3, 2017, 1:35 - 2:00 PM Location: Room 152, Level 1, Washington Convention Center Presentation: Major Symposium

Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.

http://www.bivonalab.net/

__________________________________________________________________________

Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)

Authors*: Libby Morimoto, David Zava, Katherine McGlynn, Frank Stanczyk, Joseph Wiemels, Xiaomei Ma, Catherine Metayer


Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.

http://profiles.ucsf.edu/joe.wiemels

Presentations


Effects of tobacco smoking and alcohol consumption on risks of CYP1B1 polymorphisms for prostate cancer

Authors*: Taku Kato, Yutaka Hashimoto, Shigekatsu Maekawa, Marisa Shiina, Mitsuho Imai-Sumida, Pritha Dasgupta, Priyanka Kulkarni, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Sharryari, Guoren Deng, Rajvir Dahiya, Yuichiro Tanaka


Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.

https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/

__________________________________________________________________________

The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a therapeutic opportunity in prostate cancer

Authors*: Julia Dancourt, Anirban Sahu, John R. Prensner, Benjamin Chandler, Qi Cao, Nithin Edara, Udit Singhal, Matthew K. Lyer2, Rohit Malik, Xuhong Cao, Saravana M. Dhanasekaran, Yashar S. Niknafs, Shuang Zhao, Corey Speers, Arul M. Chinnaiyan, Felix Y. Feng


Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.

https://radonc.ucsf.edu/felix-feng

Presentations


Preclinical efficacy of daratumumab in acute lymphoblastic leukemia

Authors*: Karen Lee Bride, Tiffaney Vincent, Soo-Yeon L. Im, Tori Fuller, Theresa Ryan, David M. Barrett, Shannon L. Maude, Mignon L. Loh, Michelle L. Hermiston, Stephan A. Grupp, Brent L. Wood, David T. Teachey


Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children’s Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials for children, adolescents, and young adults.

http://cancer.ucsf.edu/people/profiles/loh_mignon.3407

__________________________________________________________________________

STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions

Authors*: Alexander Drilon, Kamalesh Kumar Sankhala, Stephen V. Liu, Byoung Chul Cho, Collin Blakely, Cheng E. Chee, Marwan Fakih, Jonathan Polikoff, Zachary Hornby, Lisa Schechet, David Luo, Edna Chow Maneval, Pratik S. Multani, Robert C. Doebele

Presentation #: CT060 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pmLocation: Section 33 Presentation: Poster Session/ Board #10

Blakely Research Interests: The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients. My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer

http://top.ucsf.edu/meet-the-team/medical-oncologists/collin-blakely,-md,-phd.aspx

Presentations


COP1 E3 ligase modulates response to oncogenic MAPK pathway

Authors*: Manasi K. Mayekar, Trever Bivona


Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.

http://www.bivonalab.net/

Presentations


Characterizing tumor-adjacent normal tissue: Is it really normal?

Authors*: Dvir Aran

Presentation #:Presentation Date/Time: April 4, 2017, 7:00 - 8:00 AMLocation: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Session

Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to truly novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab uses the bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic, phenotypic, and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed tools for indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to explore human physiology using electronic health record data and in the medical risk estimation from whole genomes.

http://buttelab.ucsf.edu

__________________________________________________________________________

Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis

Authors*: Victoria E. Wang, John Doench, David Root, Rene Bernards, Jeffrey Settleman, Frank McCormick


Tuesday, April 4, 2017

Presentations


Genistein inhibits renal cancer progression through long non-coding RNA HOTAIR suppression

Authors*: Mitsuho Imai-Sumida, Shahana Majid, Pritha Dasgupta, Priyanka Kulkarni, Sharanjot Saini, Divya Bhagirath, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Yuichiro Tanaka, Rajvir Dahiya, Soichiro Yamamura


__________________________________________________________________________

LncRNA as potential target in drug-resistant melanomas

Authors*: Rosaura Esteve-Puig, Martina Sanlorenzo, Igor Vujic, Kevin Lai1,Marin Vujic, Dallas Mould, Kevin Lin, Juan Oses-Prieto, Shreya Chand, Christian Posch, Alma Burlingame, Susana Ortiz-Urda


Ortiz-Urda Research Interests: The Ortiz lab is interested in the study of the functions of promoter and intronic sequences of melanoma related genes. Our lab studies the mechanisms of cancer progression and the resistance mechanisms to drugs. In addition, Ortiz’s lab uses novel nanotechnology approaches to detect mutations and to deliver specific drugs to the cells of interest. To study cancer progression, the Ortiz lab uses epithelial tissue and organotypic constructs as a model system. The latter encompass human skin regenerated on immune-deficient mice. Grafts can express different combination of genes allowing this the elucidation of factors that stimulate tumor progression. Furthermore, the Ortiz lab uses laser micro-dissection to study single cell genetics. In order to elucidate mechanisms of resistance to targeted therapeutics the Ortiz lab analyzes resistance melanoma cell lines at the level of genome and transcriptome.

http://cancer.ucsf.edu/research/ortiz-lab

Presentations


Splice expression variation analysis (SEVA) for differential gene isoform usage in cancer

Authors*: Bahman Afsari, Theresa Guo, Michael Considine, Dylan Kelley, Emily Flam, Liliana Florea, Patrick Ha, Donald Geman, Michael F. Ochs, Joseph A. Califano, Daria A. Gaykalova, Alexander V. Favorov, Elana J. Fertig


Ha Research Interests: Dr. Ha’s lab interests align with his clinical practice of managing patients with complex head and neck cancers. He has had multiple NIH grants examining the molecular underpinnings of salivary gland adenoid cystic carcinoma in order to learn more about this rare but deadly disease. He serves on the editorial board of several journals including Head and Neck and Oral Oncology, and is now serving as the Chief of Head and Neck Surgical Oncology at the University of California San Francisco.

http://ohns.ucsf.edu/patrick-ha

__________________________________________________________________________

Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer immunologic milieu

Authors*: Noemi Andor, Erin Simonds, Jiamin Chen, Christina Wood, Susan Grimes, Debra Czerwinski, Grace Zheng, Ronald Levy, Hanlee P. Ji


Simonds Research Interests: I apply single-cell analysis techniques to understand how phenotypic heterogeneity contributes to cancer growth and resistance to therapy. I helped develop single-cell assays to study signaling in the healthy immune system, and in childhood leukemias and I am applying these same approaches to investigate phenotypic plasticity and immune infiltration in glioblastoma, the most common and lethal brain tumor. Many of my experiments are enabled by a next-generation flow cytometry platform (CyTOF mass cytometry), which can measure up to 42 protein expression and intracellular signaling markers at the single-cell level in millions of cancer cells. This platform provides detailed biochemical profiles of rare and complex samples, uncovering subpopulations that would have been overlooked by classical bulk protein and genetic assays.

http://profiles.ucsf.edu/erin.simonds#narrative

Presentations


Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma

Authors*: Zinal Chheda, Gary Kohanbash, John Sidney, Kaori Okada, Naznin Jahan, Diego Carrera, Payal Watchmaker, Kira Downey, Shuming Liu, Shruti Shrivastav, Sabine Mueller, Ian F. Pollack, Angel M. Carcaboso, Alessandro Sette, Yafei Hou, Hideho Okada




__________________________________________________________________________

A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas

Authors*: Sriram Venneti, Jill Bayliss, Piali Mukherjee, Chao Lu, Siddhant Jain, Chan Chung, Daniel Martinez, Benjamin Sabari, Ashley Margol, Pooja Panwalkar, Abhijit Paroloia, Melike Pekmezci, Richard Mc Eachin, Marcin Cieslik, Benita Tamrazi, Benjamin Garcia, Gaspare La Rocca, Mariarita Santi, Peter Lewis, Cynthia Hawkins, Ari Melnick, C. David Allis, Craig B. Thompson, Arul Chinnaiyan, Alexander R. Judkins


Pekmezci Research Interests: Dr. Pekmezci is a clinical Neuropathologist and Ophthalmic Pathologist, who is involved in translational research with specific focus on diagnostic and prognostic markers of CNS neoplasms. She has been particularly interested in molecular classification and grading schemes of diffuse gliomas. In addition, her ongoing research includes diagnostic and prognostic markers of ocular surface neoplasms and uveal melanomas.

https://www.pathology.ucsf.edu/about/faculty/pathology-mpekmezci.html

Presentations


A novel combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers

Authors*: Dhruba Deb, Satwik Rajaram, Jill E. Larsen, Patrick P. Dospoy, Rossella Marullo, Longshan Li, Kimberley Avila, Leandro Cerchietti, John D. Minna1, Lani F. Wu, Steven J. Altschuler


Altschuler and Wu Lab Research Interests: Over the past decade, our labs pioneered approaches for scalable, microscopy-based drug discovery. We also pioneered experimental, computational and theoretical approaches for identifying functional roles in patterns of cellular heterogeneity. We showed that patterns of cell-cell differences can reveal hidden biological information about how cells make decisions and serve as an informative readout of disease progression and drug response. Methodologies developed in our labs have been widely adapted in academics and industry.

http://cancer.ucsf.edu/people/profiles/altschuler_steven.5588

__________________________________________________________________________

NCoR2 regulates glioblastoma progression and treatment resistance

Authors*: Shelly Kaushik, Joanna J. Phillips, Valerie M. Weaver




Presentations


Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations

Authors*: Dejan Juric, Mario Campone, Pamela Munster, Roohi Ismail-Khan, Laura Garcia Estévez, Mariana Chavez-MacGregor, Antonio Frassoldati, Rina Hui, Ingrid A. Mayer, Javier Cortés, Anthony Gonçalves, Richard H. De Boer, Luc Dirix, Sara M. Tolaney, Soo Chin Lee, Michela Maur, Yingbo Wang, Faye Su, Jason R. Dobson, Caroline Germa, Becker Hewes, Aditya Bardia


Munster Research Interests: Our lab is interested in developing novel strategies to overcome hormone therapy resistance in breast cancer.

http://cancer.ucsf.edu/people/profiles/munster_pamela.3449

__________________________________________________________________________

Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors

Authors*: Shilpa Gupta, Juneko Grilley-Olson, David Hong, Aurélien Marabelle, Pamela Munster, Rahul Aggarwal, Sandrine Aspeslagh, Robert G. Dixon, Manish Patel, Vivek Subbiah, Chris Morehouse, Yuling Wu, Jiping Zha, Leo Tseng, Zachary A. Cooper, Shannon Morris, Joshua Brody


Presentations


Precision medicine lessons from window-of-opportunity trials

Authors*: Jennifer Rubin Grandis

Presentation #:Presentation Date/Time: April 4, 2017, 9:15 - 9:45 AM Location: Hall D-E, Level 2, Washington Convention Center Presentation: Plenary Session

__________________________________________________________________________

Post-radiation mutational signatures

Authors*: Jean L. Nakamura

Presentation #:Presentation Date/Time: April 4, 2017, 12:04 - 12:30 PM Location: East Salon C, Level 1, Washington Convention Center Presentation: Special Session

Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using this information to develop better therapies. A second area of research is trying to understand why second cancers develop in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we expect to understand the biological processes leading to second cancers, and one day prevent these complications.

https://radonc.ucsf.edu/jean-nakamura

Presentations


Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?

Authors*: Elad Ziv

Presentation #: Presentation Date/Time: April 4, 2017, 11:00 - 11:20 AM Location: Room 206, Level 2, Washington Convention Center Presentation: Major Symposium

Ziv Research Interests: Dr. Ziv joined the faculty at UCSF in 2001. His group focuses on identifying genetic variations that underlie risk for malignancies by using insights from epidemiology and population genetics. A major interest has been genetic susceptibility to breast cancer among Latinas. Using a combination of admixture mapping and genome wide association, they have identified genetic variants that are unique among Latinas and are associated with strong protection against breast cancer susceptibility. They are currently using a whole exome sequencing approach to identify breast cancer risk variants among Latinas. Dr. Ziv’s group has successfully mapped the genes for ethnic neutropenia in African Americans. They are also currently studying the genetic variation underlying multiple myeloma susceptibility and progression.

http://cancer.ucsf.edu/people/profiles/ziv_elad.3779

__________________________________________________________________________

“Weak links” in cancer proteostasis networks as new therapeutic targets

Authors*: Martin Kampmann

Presentation #: Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PM Location: Marquis Ballroom Salons 1-2, Meeting Level 2, Marriott Marquis DC Presentation: Special Session

Kampmann Research Interests: In our research, we ask how cells maintain their proteins in a functional and balanced state. In human cells, this is accomplished by a network of over 1,000 different factors called the proteostasis network. Our goal is to understand how this network functions, and how it is challenged and rewired in disease states, in particular cancer and neurodegenerative diseases. Our functional genomics technology, which integrates CRISPR/Cas9-based control of gene function and large-scale genetic interaction maps, enables us to elucidate dynamic networks and to pinpoint nodes that are potential therapeutic targets. We use biochemistry, biophysics and cell biology to “zoom in” on individual nodes of the network and to reveal their mechanism of action.

http://kampmannlab.ucsf.edu

Presentations


Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine

Authors*: Laura Fejerman

Presentation #:Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PMLocation: Room 206, Level 2, Washington Convention CenterPresentation Type: Major Symposium

Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.

http://fejerman.ucsf.edu

__________________________________________________________________________

CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Authors*: Leisha Emens, John Powderly, I2, Lawrence Fong, Joshua Brody, Patrick Forde, Matthew Hellmann, Brett Hughes, Shivaani Kummar, Sherene Loi, Jason Luke, Daruka Mahadevan, Benjamin Markman, Ian McCaffery, Richard Miller, Ginna Laport

Presentation #: CT119 Presentation Date/Time: April 4, 2017, 12:18 - 12:33 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Clinical Trials Plenary Session



Presentations


Vaccination in patients with low-grade glioma aiming at prevention of high-grade transformation

Authors*: Hideho Okada

Presentation #:Presentation Date/Time: April 4, 2017, 1:25 - 1:45 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Rapid Advances in Prevention Research



__________________________________________________________________________

Overcoming kinase inhibitor resistance and dealing with biologic redundancy: mTOR and K-Ras

Authors*: Kevan Michael Shokat

Presentation #: Presentation Date/Time: April 4, 2017, 2:05 - 2:30 PM Location: Room 207, Level 2, Washington Convention Center Presentation: Major Symposium

Presentations


Identifying allosteric modulators of KRas using second harmonic generation

Authors*: Elizabeth Donohue Vo, Gabriel Besserer Mercado, Patrick Alexander, Ben Moree, Que Van, Andrew G. Stephen, Joshua Salafsky, Frank McCormick


__________________________________________________________________________

Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy

Authors*: Christian Njatcha, Mariya Farooqui, Jennifer R. Grandis, Jill M. Siegfried


Presentations


Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma

Authors*: Rachel A. O’Keefe, Neil Bhola, Toni M. Brand, Yan Zeng, Daniel E. Johnson, Jennifer R. Grandis


Grandis Research Interests: Cetuximab is an EGFR monoclonal antibody that is FDA-approved for the treatment of head and neck cancer. Despite ubiquitous over expression of EGFR in head and neck cancers, only a subset of patients respond to this drug and resistance mechanisms are incompletely understood. The Grandis lab has accumulated evidence that secretion of interleukin 6 (IL6), with subsequent oncogenic signaling represents a potential pathway of cetuximab resistance where co-targeting IL6/ILR-receptor may represent a plausible therapeutic strategy.

http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048

__________________________________________________________________________

Application of convolutional neural networks to breast biopsies to uncover tissue correlates of mammographic breast density

Authors*: Maeve Mullooly, Babak Ehteshami Bejnordi, Maya Palakal, Pamela M. Vacek, Donald L. Weaver, John A. Shepherd, Bo Fan, Amir Pasha Mahmoudzadeh, Jeff Wang, Jason M. Johnson, Sally D. Herschorn, Brian L. Sprague, Ruth M. Pfeiffer, Louise A. Brinton, Mark E. Sherman, Andrew Beck, Gretchen L. Gierach


Shepherd Research Interests: Dr. Shepherd’s research interests involve quantitative imaging methods for tissue composition using x-rays. His mammographic methods are used extensively for research around the world and in the San Francisco Mammography Registry Program. Dr. Shepherd’s efforts are focused on the technical imaging aspects of the measurements of the body composition and the translation of these measurements into different fields of study. He has present and future research projects in the following areas: breast cancer risk and detection using breast density and tissue texture measures; dual-energy x-ray diagnostic mammography for characterizing compositional signatures of cancer lesions; total body protein measures, body shape analysis and metabolic diseases; statistics of quality assurance and quality control for quantitative measurements.

https://radiology.ucsf.edu/people/john-shepherd

Presentations


Exosomal miR-3622a as prognostic marker in prostate cancer

Authors*: Thao Yang, Divya Bhagirath, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Varahram Shahryari, Marisa Shiina, Yutaka Hashimoto, Priyanka Kulkarni, Pritha Dasgupta, Mitsuho Imai-Sumida, Soichiro Yamamura, Z Laura Tabatabai, Kirsten Greene, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini


Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression, recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key microRNAs in prostate cancer stem cells.

https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/

__________________________________________________________________________

KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases (MNKs) in a PI3K-dependent, AKT-independent manner

Authors*: Jillian M. Silva, Rachel K. Bagni, Davide Ruggero, Frank McCormick


Presentations


Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas

Authors*: Chen-Yen Yang, Linlin Wang, Laura Pincus, Frank McCormick, Ryan Gill, Wei Ai


__________________________________________________________________________

Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivors

Authors*: Natacha Le Moan, Philberta Leung, Sarah Ng, Tina Davis, Carol Liang, Jonathan W. Winger, Stephen P. L. Cary, Nicolas Butowski, Ana Krtolica


Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research in neuro-oncology and an extensive UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at national and international meetings.

https://www.ucsfhealth.org/nicholas.butowski

Presentations


Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells

Authors*: Kelvin K. Tsai, Tze-Sian Chan, Chung-Chi Hsu, Vincent C. Pai, Shenq-Shyang Huang, Valerie M. Weaver




__________________________________________________________________________

A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of pediatric cancer genomic data

Authors*: Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John Vivian, Isabel Bjork, Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-Cordero, David Haussler




Presentations


Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer

Authors*: Emanuela Dylgjeri, Jonathan F. Goodwin, Christopher M. McNair, Ayesha A. Shafi, Vishal Kothari, Felix Feng, Dana Rathkop, Karen Knudsen




__________________________________________________________________________

Technologies for Defining the Cancer Interactome

Authors*: Nevan J. Krogan

Presentation #:Presentation Date/Time: April 4, 2017, 2:45 - 4:45 PMLocation: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Session

Krogan Research Interests: Research in the Krogan lab focuses on high-throughput network biology to derive mechanistic insights into cellular processes and disease conditions, with a particular emphasis on cancer, pathogenesis, psychiatric disorders and heart disease. Cancer research and treatment is increasingly dependent on knowledge of biological networks of multiple types, including physical interactions among proteins and synthetic-lethal and epistatic interactions among genes. Dr. Krogan is Co-Director of the Cancer Cell Map Initiative (CCMI), which aims to comprehensively detail these complex interactions among cancer genes and proteins using a combination of physical interaction, genetic interaction, and computational approaches. This work will enable the analysis of cancer molecular networks with a view towards pathway and network-based personalized therapy.

http://kroganlab.ucsf.edu

Presentations


Computational detection of oncogene‐centric pathway members

Authors*: Joshua Broyde, David Simpson, Diana Murray, Alexander Lachmann, Federico M. Giorgi, Barry Honig, Alejandro E. Sweet-Cordero, Andrea Califano

Presentation #:Presentation Date/Time: April 4, 2017, 4:05 – 4:20Location: Room 147, Level 1, Washington Convention Center Presentation: Minisymposium



__________________________________________________________________________

Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients

Authors*: Sabine Mueller, Charles G. Mullighan - Invited Speakers

Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM Location: Room 150, Level 1, Washington Convention Center Presentation: Forum

Mueller Research Interests: The laboratory of Dr. Sabine Mueller focuses on translational research in pediatric neuro-oncology. A key focus is the development and characterization of patient derived xenograft (PDX) models for diffuse intrinsic pontine gliomas (DIPG) and other pediatric high grade gliomas (pHGGs). In particular, the Mueller lab investigates the genomic heterogeneity of DIPGs and other pHGGs. Additionally, they are exploring the utility of liquid biopsies by assessing circulating tumor DNA and correlating this with disease response. Further, the laboratory is exploring central nervous system (CNS) directed delivery strategies, such as convection enhanced delivery (CED) in combination with nanotechnology, in these PDX models. The laboratory has several industry partnerships to test new agents as single agents and in combination therapy strategies with other agents as well as radiation therapy.

http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800

Presentations


Early Detection of Lethal Cancers: Separating the Wheat from the Chaff

Authors*: Avrum E. Spira, Laura J. Esserman - Invited Speakers

Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM Location: East Salon A-B, Level 1, Washington Convention Center Presentation: Forum

__________________________________________________________________________

Genomics and the Environment: Moving toward Precision Medicine in the Context of Health Disparities

Authors*: Laura Fejerman

Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PMLocation: Room 152, Level 1, Washington Convention CenterPresentation Type: Forum



Presentations


Spatial-mechanical regulation of tumor dormancy and metastases

Authors*: Valerie M Weaver

Presentation #: Presentation Date/Time: April 4, 2017, 6:50 - 7:10 PM Location: Marquis Ballroom Salons 6-10, Meeting Level 2, Marriott Marquis DC Presentation: Town Meeting



Presentations


Breast cancer characteristics among Indigenous American women from Peru

Authors*: Lizeth I. Tamayo, Tatiana Vidaurr2, Jeannie N. Vásquez, Sandro Casavilca, Jessica I. A. Palomino, Monica Calderon, Garth H. Rauscher, Laura Fejerman




__________________________________________________________________________

Association of physical activity with risk of prostate cancer defined by TMPRSS2:ERG

Authors*: Claire H. Pernar, Ericka M. Ebot, Andreas Pettersson, Rebecca E. Graff, Thomas U. Ahearn, Amparo G. Gonzalez-Feliciano, Sarah C. Markt, Kathryn M. Wilson, Stephen Finn, Michelangelo Fiorentino, Edward L. Giovannucci, Lorelei A. Mucci




Wednesday, April 5, 2017

Presentations


An exosomal biomarker for prostate cancer

Authors*: Divya Bhagirath, Thao Yang, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Yutaka Hashimoto, Priyanka Kulkarni, Pritha Dasgupta, Marisa Shiina, Varahram Shahryari, Mitsuho Imai-Sumida, Soichiro Yamamura, Z Laura Tabatabai, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini.


Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression, recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key microRNAs in prostate cancer stem cells.

https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/

__________________________________________________________________________

VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis, and predicts poor prognosis

Authors*: Yozo Mitsui, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Mitsuho Imai Sumida, Ryan Kenji Wong, Soichiro Yamamura, Varahram Shahryari, Shahana Majid, Sharanjot Saini, Guoren Deng, Rajvir Dahiya, Koichi Nakajima, Yuichiro Tanaka


Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.

https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/

Presentations


Disrupting the Aurora kinase A interactome in pediatric cancer

Authors*: Sucheta Mukherjee, Carolyn Tu, Clay Gustafson


Gustafon Research Interests: The Gustafson lab focuses on new basic biological discoveries in cancer and leveraging these to develop novel therapies. One focus has been the discovery and development of novel targeted therapies to treat MYC driven cancers, particularly neuroblastoma. Pathways which regulate MYC proteins are central to neuroblastoma, as well as a wide array of other pediatric and adult cancers. MYCN is prominently amplified in high-risk neuroblastoma and neuroblastoma is widely considered a model MYC-protein driven disease. Most recently we have discovered a new class of conformation-disrupting Aurora A inhibitors (CD-AURKi) with CD532 as our lead compound. These CD-AURKi potently inhibit Aurora Kinase A and downregulates MYCN protein in neuroblastoma cells. Using co-crystal structures, cell culture models, and structure-activity relationships, we have shown that CD532 acts via a novel allosteric mechanism whereby a kinase inhibitor is used to drug an undruggable transcription factor.

http://gustafsonlab.ucsf.edu

__________________________________________________________________________

Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC)

Authors*: Benjamin C. Chandler, Corey W. Speers, Shuang G. Zhao, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati, Daniel Spratt, Daniel Wahl, Daniel Hayes, Felix Y. Feng, Lori J. Pierce




Presentations


Cdk4/6 kinase inhibitor resistance in prostate cancer

Authors*: Renee de Leeuw, Matthew J. Schiewer, Christopher McNair, Michael A. Augello, Akihiro Yoshida, Edward S. Hazard, Sean Courtney, Gerard T. Hardiman, Justin Drake, Felix Y. Feng, Scott Tomlins, Maha H. Hussain, J. Alan Diehl, William K. Kelly, Karen E. Knudsen




__________________________________________________________________________

Tumor microenvironment modulates RTK signaling

Authors*: Dhruv Thakar, Shalini T. Low-Nam, Jay T. Groves, Valerie M. Weaver




Presentations


A novel oncomiR negatively regulates PTEN pathway in prostate cancer

Authors*: Nadeem S. Bhat, Melissa Colden, Prerna Arora, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Soichiro Yamamura, Yuichiro Tanaka, Taku Katu, Yutaka Hashimoto, Marisa Shiina, Priyanka Kulkarni, Pritha Dasgupta, Mitsuho Imai-sumida, Shigekatsu Maekawa, Guoren Deng, Rajvir Dahiya, Shahana Majid

Presentation #: LB-326 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 36 Presentation: Poster Session/ Board #12

Majid Research Interests: The Majid lab, located Urology Research Center at the VAMC/UCSF, focuses in the area of urological cancers to understand the etiology and to develop novel molecular biomarkers for initiation, progression and metastasis with special emphasis on prostate cancer. We have been working in the field of microRNAs, genetics and epigenetics of urologic cancers. Cancer progression markers are identified by employing genome-wide approaches, and utilizing cells culture and mouse models as well as tissues from patients. The objective of the lab is to identify novel therapeutic targets or valuable biomarkers to establish rational therapeutic strategies for the diagnosis and treatment of cancer.

http://profiles.ucsf.edu/shahana.majid

__________________________________________________________________________

Glioblastoma: Where we are, where we have been, and what is next

Authors*: Michael Prados

Presentation #:Presentation Date/Time: April 5, 2017, 10:15 - 10:30 AM Location: Room 145, Level 1, Washington Convention CenterPresentation: Recent Advances in Organ Site Research

Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

http://cancer.ucsf.edu/people/profiles/prados_michael.3603

56

Rahul Aggarwal, MDCT091 Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors

Wei Ai, MD4589 Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas

Mary Helen Barcellos-Hoff, PhD831 TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM

Neil Bhola, PhD95 Targeting BRD4 overcomes cetuximab resistance in HNSCC

Trever Bivona, MD, PhD— Mechanisms of residual disease during targeted therapy

LB-124 COP1 E3 ligase modulates response to oncogenic MAPK pathway

Collin Blakely, MDCT060 STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions

Jeffrey Bluestone, PhD683A Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response

Nicolas Butowski, MD4686 Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivors

Atul Butte, MD, PhD— Characterizing tumor-adjacent normal tissue: Is it really normal?

LB-006 Oncology model fidelity scores

Rajvir Dahiya, PhD462 The role of miR-24 as a race-related genetic factor in prostate cancer

483 Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African Americans and Caucasians

Summary of Abstracts

Summary of Abstracts by Faculty Member

57


Adil Daud, MD— Response to checkpoint therapy and exhausted CTL in the tumor microenvironment

Michel DuPage, PhD1014 Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity

Laura Esserman, MD, MBA— Early Detection of Lethal Cancers: Separating the Wheat from the Chaff

Laura Fejerman, PhD— Genomics and the Environment: Moving toward Precision Medicine in the Context of Health Disparities

— Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine

5275 Breast cancer characteristics among Indigenous American women from Peru

Felix Feng, MD2546 The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a therapeutic opportunity in prostate cancer

5839 Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC)

5874 Cdk4/6 kinase inhibitor resistance in prostate cancer

LB-086 PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity

LB-264 Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer

Lawrence Fong, MD549 Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients

1694 Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients

CT031 A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)

CT119 CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Jason Gestwicki, PhD1180 Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer

Jennifer Grandis, MD— Precision medicine lessons from window-of-opportunity trials

1779 Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma

4101 Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy

4108 Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma

58


Clay Gustafson, MD, PhD5818 Disrupting the Aurora kinase A interactome in pediatric cancer

Patrick Ha, MD3577 Splice expression variation analysis (SEVA) for differential gene isoform usage in cancer

Tonya Kaltenbach, MD281 Site specific risk factors for colorectal cancer

Martin Kampmann, PhD— “Weak links” in cancer proteostasis networks as new therapeutic targets

Nevan Krogan, PhD— Technologies for Defining the Cancer Interactome

Mignon Loh, MD2642 Preclinical efficacy of daratumumab in acute lymphoblastic leukemia

Shahana Majid, PhDLB-326 A novel oncomiR negatively regulates PTEN pathway in prostate cancer

Frank McCormick, PhD435 Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells

— The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research

1209 FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination

1366 Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS

1370 EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling

3182 Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis

4018 Identifying allosteric modulators of KRas using second harmonic generation

4484 KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases (MNKs) in a PI3K-dependent, AKT-independent manner

Michael McManus, PhD1006 Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Sabine Mueller, MD— Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients

59


Pamela Munster, MDCT087 Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations

Jean Nakamura, MD1356 Variable drug responses characterize the functional heterogeneity of Nf1 null tumors

— Post-radiation mutational signatures

Hideho Okada, MD, PhD— Brain cancer immunotherapy

3767 Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma

— Vaccination in patients with low-grade glioma aiming at prevention of high-grade transformation

Susana Ortiz-Urda, MD3493 LncRNA as potential target in drug-resistant melanomas

Melike Pekmezci, MD3863 A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas

Claudia Petritsch, PhD916 Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin

Michael Prados, MDLB-008 The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich ecosystem for collaborative discovery in the cloud

— Glioblastoma: Where we are, where we have been, and what is next

Davide Ruggero, PhD— Translating the cancer genome one codon at a time and its therapeutic implications

Hope Rugo, MD— Transforming breast cancer treatment with CDK4/6 inhibitors

CT044 MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease

Amit Sabnis, MDCT030 STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions

60


Sharanjot Saini, PhD4435 Exosomal miR-3622a as prognostic marker in prostate cancer

5448 An exosomal biomarker for prostate cancer

John Shepherd, PhD4235 Application of convolutional neural networks to breast biopsies to uncover tissue correlates of mammographic breast density

Kevan Shokat, PhD— Overcoming kinase inhibitor resistance and dealing with biologic redundancy: mTOR and K-Ras

Erin Simonds, PhD3693 Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer immunologic milieu

Alejandro Sweet-Cordero, MD1948 Tumor-specific copy number alterations uncover therapeutic opportunities in osteosarcoma

4890 A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of pediatric cancer genomic data

— Computational detection of oncogene‐centric pathway members

Eric Talevich, PhDLB-044 Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial

Yuichiro Tanaka, PhD2288 Effects of tobacco smoking and alcohol consumption on risks of CYP1B1 polymorphisms for prostate cancer

5749 VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis, and predicts poor prognosis

Margaret Tempero, MD— A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma

Laura van’t Veer, PhDLB-102 Landscape analysis of the initial data release from AACR Project GENIE

Kyle Walsh, PhD1320 Non-additive and interaction effects of HLA class 2 polymorphism contributing to risk of glioma

61


Valerie Weaver, PhD— Tissue Tension: The extracellular martrix and PDAC phenotype

— Forcing tumor progression and aggression

3985 NCoR2 regulates glioblastoma progression and treatment resistance

4763 Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells

— Spatial-mechanical regulation of tumor dormancy and metastases

5912 Tumor microenvironment modulates RTK signaling

Jonathan Weissman, PhD— Retooling CRISPR to turn genes on and off

Joseph Wiemels, PhD1273 Pathway analysis of insulin-like growth factor candidate genes and risk of pediatric rhabdomyosarcoma

2263 Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)

John Witte, PhD1297 Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening

1310 Identification of pleiotropic cancer susceptibility variants from genome-wide association studies reveals functional characteristics

1316 Germline genetic signals across multiple aggressive prostate cancer phenotypes

5317 Association of physical activity with risk of prostate cancer defined by TMPRSS2:ERG

Soichiro Yamamura, PhD199 Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways

3449 Genistein inhibits renal cancer progression through long non-coding RNA HOTAIR suppression

Elad Ziv, MD— Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?

Lani Wu, PhD/Steven Altschuler, PhD3950 A novel combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER...

Documents

Transcript of UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER...